Loading...
XTSXMDX
Market cap21mUSD
Oct 20, Last price  
0.12CAD
Name

Medx Health Corp

Chart & Performance

D1W1MN
XTSX:MDX chart
P/E
P/S
48.73
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
8.58%
Rev. gr., 5y
-15.95%
Revenues
456k
-10.68%
2,742,3792,932,1252,596,3811,055,7921,149,478451,375657,358872,584728,286579,645877,7321,171,421817,0551,093,2391,087,426860,248530,066563,101510,606456,088
Net income
-5m
L-10.77%
-400,657-1,768,282-1,558,787-2,096,021-2,766,736-2,559,007-992,574-868,089-539,224-1,892,345-204,577-499,249-1,335,293-1,604,438-4,186,573-3,276,350-3,199,476-5,323,540-5,133,699-4,580,548
CFO
-3m
L+22.18%
173,711-1,550,811-103,168-607,265-3,300,400-48,389-518,59884,896-59,488-141,942-864,076-536,528-1,331,403-1,470,990-2,606,542-1,324,793-2,908,871-4,516,708-2,800,837-3,422,138
Earnings
May 29, 2025

Profile

MedX Health Corp, a medical device and software company, develops, manufactures, and markets skin related screening tools and phototherapy devices for pain relief and tissue repair in Canada, the United States, and internationally. The company offers SIAscopy, a medical device technology used to scan skin for suspicious moles and lesions; phototherapeutic medical devices, which use light energy in lower-level laser and LED to provide treatment for pain and tissue damage in the rehabilitation market; and SIAMETRICS, SIMSYS, and MoleMate, which creates real-time images for physicians and dermatologists to evaluate various types of moles or lesions within seconds. It operates DermSecure telemedicine platform that enables the web-based operation of its SIAscopy scanning technology and allows the company to deploy its technology in networks of third-party locations from which patients' mole and lesion images along with other relevant patient information can be connected to specialist physicians for remote assessment. The company was incorporated in 1999 and is headquartered in Mississauga, Canada.
IPO date
Feb 12, 2008
Employees
Domiciled in
CA
Incorporated in
CA

Valuation

Title
CAD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
456
-10.68%
511
-9.32%
Cost of revenue
3,070
3,894
Unusual Expense (Income)
NOPBT
(2,614)
(3,384)
NOPBT Margin
Operating Taxes
1,269
Tax Rate
NOPAT
(2,614)
(4,653)
Net income
(4,581)
-10.77%
(5,134)
-3.57%
Dividends
Dividend yield
Proceeds from repurchase of equity
413
20
BB yield
Debt
Debt current
4,962
4,120
Long-term debt
972
967
Deferred revenue
Other long-term liabilities
1
Net debt
5,796
4,945
Cash flow
Cash from operating activities
(3,422)
(2,801)
CAPEX
Cash from investing activities
Cash from financing activities
3,418
2,837
FCF
(3,405)
(3,619)
Balance
Cash
138
142
Long term investments
Excess cash
115
117
Stockholders' equity
(23,898)
(17,927)
Invested Capital
22,600
15,205
ROIC
ROCE
201.42%
124.33%
EV
Common stock shares outstanding
196,708
183,742
Price
Market cap
EV
EBITDA
(2,562)
(3,332)
EV/EBITDA
Interest
2,150
1,269
Interest/NOPBT